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A major drawback in coronary atherosclerosis (ATS) research is the difficulty of investigating early phase of plaque growth
and related features in the clinical context. In this study, secreted proteins from atherosclerotic coronary arteries in a
hypercholesterolemic swinemodel were characterized by a proteomics approach and their expression was correlated to site-specific
ATS stage and extent. A wide coronary artery map of secreted proteins has been obtained in high fat (HF) diet induced ATS swine
model and a significantly different expression ofmany proteins related to vascular smoothmuscle cell (VSMC) activation/migration
has been identified. Significant associations with ATS stage of HF coronary lesions were found for several VSMC-derived proteins
and validated for chitinase 3 like protein 1 (CHI3L1) by tissue immunoexpression. A direct correlation (𝑅2 = 0.85) was evidenced
with intima to media thickness ratio values and ELISA confirmed the higher blood concentrations of CHI3L1 in HF cases. These
findings confirmed the pivotal role of VSMCs in coronary plaque development and demonstrated a strong site-specific relation
between VSMC-secreted CHI3L1 and lesion grade, suggesting that this protein could be proposed as a useful biomarker for
diagnosing and staging of atherosclerotic lesions in coronary artery disease.
1. Introduction
Coronary atherosclerosis (ATS) is the underlying pathology
of major acute events associated with thrombotic obstruction
of vessel lumen and a leading cause of morbidity and
mortality in Western countries [1, 2].
Identification of molecular factors associated with coro-
nary atherogenesis (i.e., coronary plaque formation and early
progression) has relevant implications for diagnosis, preven-
tion, and treatment of overt coronary artery disease (CAD),
especially when significant associations emerge between
these factors and the ATS grade, lesion extent, and progres-
sion.
Within this context, proteome profiling represents an
interesting approach to disclose a broad spectrum of cellular
proteins and peptides and to propose putative biomarkers
[3]. Amajor obstacle in investigating coronary ATS initiation
and progression is related to the advanced stage of human
atherosclerotic samples collected at surgery and the conse-
quent difficulties in digging putative biomarkers in a complex
tissue proteome, characterized by a wide dynamic range of
concentration.The study of secreted factors in atherosclerosis
research could override the limits of a plaque proteome [4]
evidencing hidden actors and representing a valuable source
of noninvasive markers detectable in blood.
In order to reduce sample complexity in proteome studies
and to obtain human tissue representatives of the early stages
of plaque formation and progression, de la Cuesta et al.
have recently [5] analyzed the medial layer of atherosclerotic
coronary arteries by 2D-DIGE, highlighting a differential
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expression of several cytoskeleton proteins of atheroma-
adjacent VSMCs as compared to preatherosclerotic cells, and
hypothesized a key role in plaque formation by activated
VSMCs.
The same authors [6] have previously used a label-free liq-
uid chromatography approach coupled with mass spectrom-
etry (LC-MS/MS) analyses to compare the secretome data
from human atherosclerotic coronary arteries with preath-
erosclerotic coronaries and intact mammaries (collected at
autopsy) and identified four VSMC-related proteins, which
were downreleased in the pathological samples.
Both proteomics approaches highlighted the key role
of arterial VSMCs in atherosclerotic plaque initiation and
growth. Moreover, this role was related to the well-known
VSMC phenotypic heterogeneity, which accounts for various
cell activities such as proliferation, migration, and synthe-
sis/degradation of extracellular matrix (ECM) components
[7]. Indeed, according to the classical theory of atheroge-
nesis, after inflammatory cells and mediators initiate the
process by foam cell formation, the overexpression of ECM
proteoglycans (ECM-PGs), synthetized by activated VSMCs,
would enhance subendothelial lipoprotein trapping while
VSMC proliferation contributed to plaque growth and to its
evolution towards stability [8].
A clear association of the full spectrum of lesion stages
in coronary atherogenesis with known or novel molecular
factors of pathology progression is currently missing for
several reasons: (i) the inherent difficulty to investigate the
early stage of ATS [9] and to identify low-abundant cell-
secreted proteins; (ii) the limited number of studies which
have focused on protein expression in the intima layer of early
coronary lesions in humans and the even lower number of
those that have compared preatherosclerotic with advanced
coronary lesions [10–13]; (iii) the difficulty of assessing which
of the observed coronary preatherosclerotic lesions, such as
diffuse intimal thickening and fatty streaks, are prone to
progress into advanced lesions and which will remain stable
over decades, a condition that limits the identification of
informative markers of evolving lesions [9].
All these limitations in studying plaque onset and forma-
tion have encouraged the use of animalmodels, amongwhich
swine is considered the closest to human. [14]. Although
genomics and transcriptomics atherogenesis-related changes
are reported in mouse and swine models [15, 16], a wide prot-
eomics profiling of porcine coronary arteries, to identify
molecular factors and protein pathways involved in plaque
initiation and early formation, has not yet been described.
Aims of the present study are (i) to identify a molecular
map of proteins secreted by intact and atherosclerotic coro-
nary arteries of pigs fed on standard (CTRL) and hyperc-
holesterolemic (HF) diet, respectively, using a hypothesis-free
approach; (ii) to compare protein expressions of CTRL and
HF samples and to evidence differentially secreted proteins
that could be related to CAD onset and progression; and (iii)
to associate the most relevant differentially expressed pro-
teins with histomorphometrically characterized atheroscle-
rotic lesions and to identify their cellular localization by
immunohistochemistry.
2. Methods
2.1. Experimental Protocol
2.1.1. Animals and Diet. The protocol was applied to 12 male
domestic pigs of 8 to 12 weeks of age. Animals were allocated
into two groups: controls fed on standard chow (CTRL, 𝑛 = 6)
and animals fed on high fat cholesterol-enriched diet (HF,
𝑛 = 6) for 4 months (119 days). Mean baseline body weight
in the two groups was not significantly different and raised to
42 ± 7Kg and 49 ± 7Kg in CTRL and HF, respectively, at the
end of diet period (mean values ± SD, NS). High fat diet, as
compared to standard one, was supplemented with 20% lard
and 4% cholesterol (4450Kcal/kg with 54.6% of total energy
provided by fat). The plasma lipid profile was evaluated:
plasma triglycerides (TGs), high-density lipoprotein (HDL),
low-density lipoprotein (LDL), and total cholesterol (TC)
content were measured by enzymatic colorimetric reactions
using commercial kits (Synchron CX9 Pro, Beckman Coulter
Inc., USA). Values (mg/dL) in the CTRL group (𝑁 = 6, mean
± SD) were as follows: TGs: 29.5 ± 19.3; TC: 58.3 ± 4.9; HDL:
25.5 ± 4.4; LDL: 27 ± 5.5; TC/HDL ratio: 2.3 ± 0.2; values in
HF group (𝑁 = 6, mean ± SD) were as follows: TGs: 65 ± 45;
TC: 558 ± 134; HDL: 34 ± 14; LDL: 511.2 ± 133.6; TC/HDL
ratio: 19± 7. LDLwas calculated according to Friedewald et al.
[17]. Apolipoprotein A1 was measured by rate nephelometry
(BN-ProSpec, Siemens Healthcare Diagnostics, Italy): CTRL
group (𝑁 = 6, mean ± SD): 22.8 ± 8.5mg/dL; HF group
(𝑁 = 6, mean ± SD): 54.7 ± 6.4mg/dL. All values were sig-
nificantly different between CTRL and HF group.
2.1.2. Surgery. Anaesthesia was induced by intramuscular
administration of 10mg/kg of Zoletil and 0.05mg/Kg ofAtro-
pine and maintained with gas (isofluorane, nitrous oxide,
and oxygen) together with 5mg/kg/h of Propofol intravenous
infusion. Animals were mechanically ventilated (respiratory
volume: 150mL/Kg/min, respiratory rate: 15 cycles/min) and
sacrificed by KCl i.v. injection under anaesthesia.
2.1.3. Tissue Processing. The femoral artery (FA) and the
proximal tract of the right coronary artery (RCA) were
isolated and 25–30mm long segments excised and quickly
placed in serum-free medium for secreted protein collection.
Thereafter the entire heart was immersed in 5% buffered for-
malin for tissue fixation (5–7 days) and subsequent coronary
segmentation for histology and immunohistochemistry.
2.2. Secreted Protein Collection Procedure. Immediately after
heart arrest, RCA and FA segments from CTRL and HF cases
were processed according to literature and collected proteins
were analysed byHPLC-MS/MS analysis [18]. Briefly, samples
were incubated in 6-well plates in 2mL of Eagle’s Minimal
Essential Medium (Sigma-Aldrich, USA) supplemented with
Penicillin and Streptomycin, without Fetal Bovine Serum
(FBS) and Phenol Red at 37∘C in a humidified atmosphere
of 5% CO
2
. After three hours, the medium was replaced.
After 24 h, the culture medium was harvested, centrifuged at
300×g for 10min. Samples were concentrated by centrifugal
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devices Amicon Ultra-3 (Millipore, Germany) following the
manufacturer’s recommendations.
2.3. Reduction, Alkylation, and Digestion of Proteins. Each
secretome sample was processed, by preparing a solution
of 1 𝜇g/𝜇L of proteins and 40mM of ammonium hydrogen
carbonate (Sigma-Aldrich, USA). Reduction was obtained by
adding 5mM dithiothreitol to each sample, with an incu-
bation of 20min at 80∘C. Finally alkylation was obtained
by adding 10mM iodoacetamide and incubation for 30min
at 37∘C. Digestion was performed incubating the samples
overnight with 0.25mg/mL of trypsin solution at 37∘C (sub-
strate/enzyme = 100/1).
2.4. LC-MS/MS Analysis and Data Processing. Chromato-
graphic separation of digested peptides was performed
using an Ultimate 3000 nano-HPLC system (LC Packings,
DIONEX, USA) and peptides eluted from chromatographic
C18 column were directly processed using TripleTOF 5600
mass spectrometer (ABSCIEX, Canada). For each secretome
sample (CTRL 𝑁 = 6, HF FA 𝑁 = 6 and HF RCA 𝑁 = 6),
two technical replicates were injected.
The mass spectrometer was controlled by Analyst 1.6.1
software (AB SCIEX, Toronto, Canada). For positive ioniza-
tion, ion source parameters were the following: spray voltage
was 3 kV and source temperature 150∘C with curtain gas
set at 25, GS1 10, and GS2 0 psi nitrogen flow. For infor-
mation dependent acquisition (IDA) analysis, survey scans
were acquired in 250ms and 25 product ion scans were
collected if exceeding a threshold of 125 counts per second
(counts/s). The total cycle time was fixed to 1.25 s. Four time
bins were added for each scan at a pulser frequency value
of 11 kHz through monitoring of the 40GHz multichannel
TDC detector with four-anode/channel detection. Dynamic
exclusion was set to 1/2 of peak width (∼8 s), and then the
precursor was refreshed off the exclusion list.
MS/MS data were processed with ProteinPilot Software
(ABSCIEX, Canada), using the Paragon and Pro Group
Algorithms and SwissProt 2013 as protein database for Sus
scrofa.The false discovery rate (FDR) analysis was performed
using the integrated tools in ProteinPilot software and a con-
fidence level of 95% was set to exclude false positive sequence
identifications by analyzing the specificity and the quality of
results with decoy database searching. Expression data for
proteins and label-free comparative analysis were obtained
using MarkerView software 1.2.1 (ABSCIEX, Canada).
2.5. Western Blot Analysis of Secretome Samples. The same
secretome samples used for HPLC-MS analysis (CTRL, HF)
were tested on a 10% SDS-PAGE; separated proteins trans-
ferred onto a nitrocellulose membrane (Amersham, GE
Healthcare, USA) using a wet transfer system (Bio-Rad
Laboratories, USA). Membranes were blocked with 3% BSA
in TBST for 1 h at room temperature. Primary and secondary
antibodies were diluted in 3% BSA in TBST. All primary
antibodies were incubated overnight at 4∘C. HRP-conjugated
secondary antibodies (Santa Cruz Biotechnology, USA) were
incubated for 1 h at room temperature.
The following antibodies were used: CATD (C20), goat
polyclonal (Santa Cruz Biotechnology, USA), dilution 1 : 300,
and CH3L1 goat polyclonal (R&D Systems), dilution 1 : 500.
Densitometric quantification of photographic films was
performed using Quantity One 1-D Analysis Software (Bio-
Rad Laboratories, USA). Photographic films were scanned
and analysed by Quantity One 1-D Analysis Software (Bio-
Rad Laboratories, USA).
2.6. Histology and Immunohistochemistry. After incubation
for secretome analysis, all segments of RCA and FA were
placed in 5% buffered formalin and processed for paraffin
embedding: longitudinal 5 𝜇m thick consecutive sections
were obtained by a rotary microtome (MicromHM 300, Bio-
optica) and stained with Haematoxylin and Eosin (H&E)
and Masson’s trichrome stain in order to observe and mor-
phometrically assess pathologic changes. The same proce-
dure and analysis were carried out on 2 additional cross-
sectioned segments of RCA adjacent to those sampled for
secretome analysis (distal and proximal side) in each case;
other coronary samples were harvested from left main (𝑛 =
2), left anterior descending (𝑛 = 10), and left circum-
flex arteries (𝑛 = 4) in each CTRL and HF case and
processed for histology in order to morphometrically assess
overall coronary ATS burden. A total of 20 to 30 consecutive
serial sections were obtained from each segment for his-
tologic staining and immunohistochemistry. For immuno-
histochemistry, sections were placed on positively charged
slides, deparaffinized, rehydrated, and washed in distilled
water. After incubation in H
2
O
2
at room temperature, anti-
gen retrieval was accomplished (citrate buffer pH = 6 in
microwave for 10min at 500W) and then sections incubated
with diluted normal blocking serum. The following primary
antibodies were used: anti-𝛼SM-actin (alpha smooth muscle
actin, clone 1A4ADB, Serotec) as a VSMCphenotypemarker,
anti-S100 A4 (rabbit polyclonal antibody diluted 1 : 200,
Novus Biologicals) as amarker of synthetic VSMCphenotype
[19, 20], and anti-CHI3L1 (goat polyclonal antibody diluted
1 : 40, R&D Systems) as a marker derived from the results
of secretome analysis. They were applied overnight on the
slides in a 4∘Chumid chamber. Following 30min biotinylated
secondary antibody and 30min Vectastain Elite ABC reagent
incubation in Peroxidase substrate solution (DAB), slides
were counterstained with Mayer’s Haematoxylin for 1min
andmounted (Neo-EntellanMerk). Omission of the primary
antibody served as a negative control. Antibody binding is
visible as brown or dark brown stain (DAB); negative cells are
stained blue (Haematoxylin counterstain).
2.7. Morphometry and Quantitative Immunohistochemistry.
Consecutive longitudinal and cross sections of each arterial
sample were examined under a light microscope (Olympus
BX43) at 4x to 40x original magnification and digitized by a
video system (Olympus D20 camera) interfaced to Olympus
Cell Sens Dimension software for image acquisition and
analysis.
Arterial wall changes were analysed by two independent
pathologists who attempted to relate them to the current
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histological grading according to American Heart Associa-
tion (AHA) classification guidelines [8, 21].
The following morphometric indexes were calculated by
mean value of 5 consecutive cross sections of each identified
lesion at the site of its maximal extent: maximal intimal
thickness (IT), maximal intimal to media thickness ratio
(IMT ratio), cross-sectional lesion area (LA), and lesion to
intact wall area ratio (LA ratio).
All RCA segments used for secretome analysis were mor-
phometrically analysed; additional RCA, left main, left ante-
rior descending, and left circumflex artery segmentswere also
analysed to estimate overall coronary ATS burden frommor-
phometry in each case of HF group. Results were correlated
with those of corresponding coronary samples processed for
secretome analysis. A total number of 134 coronary segments
were morphometrically analysed (see Table S4 in Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2015/465242).
Quantitative analysis of antibody staining of full lesion
area was carried out by averagingmicroscopic measurements
of 3 consecutive sections of each segment, digitized at 20x
magnification under the same light source settings, and proc-
essed by semiautomatic color thresholding of Olympus
Cell Sens Dimension software: positive-staining area was
expressed as percentage of dark brown pixels of the entire
lesion area and used as a comprehensive index of antibody
binding.
Tissue codistribution and cell colocalization of different
antibodies in the same region and cell type, respectively, were
assessed by comparing them with positive tissue/cell in the
corresponding microscopic field of adjacent consecutive
sections.
2.8. ELISA of Plasma Samples. Dosage by double-antibody
sandwich enzyme-linked immunosorbent assay (ELISA) was
performed for CHI3L1. ELISA kit was used and reagents
were prepared following the manufacturer’s manual of Uscn
Life Science Inc. All standards and plasma samples collected
before surgery from the same animals (CTRL 𝑁 = 6 and
HF 𝑁 = 6) were assayed in duplicate. The OD absorbance
at 450 nm was read by a FLUOstar Omega microplate reader
(BMG Labtechmicroplate).
2.9. Data Analysis. To evaluate differentially released pro-
teins by CTRL, HF RCA, and HF FA segments (the latter
for internal control), MarkerView 1.2 software was used
and principal component analysis (PCA) was performed on
mass spectrometric data of individually different biological
samples to assess global differences between the groups
(Figure S5 in SupplementaryMaterial). Comparative analysis
in MarkerView was performed, comparing MS area of the
peptide eluted peaks with total area of the peptide peaks
for proteins. Normalization was accomplished by LC-MS
profiles (normalization based on total MS derived total ion-
current area as an estimate of total protein content). Two
technical replicates for biological sample were used and
mean values were obtained for comparative analysis (Table
S3 in SupplementaryMaterial). Principal component analysis
(PCA) was performed in order to identify groups within the
dataset. The three groups (CTRL, HF FA, and HF RCA) were
compared by 𝑡-test statistics: CTRL versus HF FA, CTRL
versus HF RCA, and HF FA versus HF RCA samples.
Paired 𝑡-test was used as statistical parameter between
the means of continuous variables to determine significant
differences between the two categories of mass spectrometric
data. Fold change > 2 and 𝑃 value < 0.05 were considered
significant to validate differences between categories.
Statistical analyses of other data were conducted using
Origin 7.0 software (Origin Lab, USA). Data were expressed
as the mean ± SD. Differences between the means of the 2
continuous variables were evaluated by Student’s 𝑡-test and
results were accepted when 𝑡-test > 95% (𝑃 value < 0.05).
Paired 𝑡-test was used for quantitative immunohistochem-
istry. Ingenuity pathway analysis (IPA, http://www.inge-
nuity.com/products/pathways analysis.html) was performed
on a restricted number of VSMC-related proteins (𝑛 = 31),
selected by their best correlation with at least one morpho-
metric index of lesion extent. The subset of chosen proteins
constituted of smooth muscle cell synthesized proteins and
their role in cell migration and proliferation and in vascular
disease was evidenced.
3. Results
3.1. Histology and Histomorphometry. Vessel segments used
for secretome analysis and adjacent segments were histologi-
cally characterized. RCA and FA of CTRL group displayed an
intact intima. Less than 2% of examined coronary segments
showed small myointimal cushions at branching points as
previously described in pigs on standard diet [22]. FA
segments of HF group evidenced intact intima in 4 cases and
Stary type I lesions in 2 cases.
Conversely, RCA from HF pigs showed atherosclerotic
changes of the intima, ranging from lesions classifiable as
Stary types I–III in 3 cases (preatheroma changes, pre-ATH)
to those resembling types IV-V atheromas in the other 3 cases
(atheroma stage, ATH).
Histologic features and average values of IMT ratio of
the segments processed for secretome analysis are shown in
Figure 1.
Classification of lesions according to Stary staging of
ATS and average histomorphometric results of RCA and FA
segments are summarized in Table 1. Average values of IT,
IMT ratio, LA, and LA ratio of RCA segments of HF group
displaying only preatheroma (pre-ATH) changes and those
with atheroma (ATH) are reported separately; the latter sub-
group shows significantly higher values.
The average values ofmorphometric indexes according to
lesion grade in all coronary segments sampled in CTRL and
HF cases are reported in Table S4 in SupplementaryMaterial.
3.2. Proteomics Profiling of Secreted Proteins and Comparative
Analysis between CTRL and HF Data. 224 proteins were
identified across all samples with a Protein Score (Confi-
dence) > 95% and local false discovery rate analysis < 1% as
stringent criterion to avoid false positives (Table S1 in Sup-
plemtaryMaterial). Proteinswere groupedusingGeneOntol-
ogy (http://www.geneontology.org) and divided in exocytosis
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Figure 1: Morphometric results (panel (a)) and histologic characterization (panels (b)–(i)) of arterial segments used for secretome analysis.
Panel (a): average values ± SD of intima tomedia ratio (IMT) atmaximal intimal thickening site in CTRLRCA,HF FA, andHFRCA segments
used for secretome analysis (𝑛 = 6 each). 𝑃 < 0.05 HF RCA versus all other segments. Panels (b)–(i): representative photomicrographs of
H&E and Masson’s trichrome stained longitudinal sections of arterial segments: intact (b) or initial type I thickening (c) in typical CTRL
RCA and HF FA segments, respectively; HF RCA segments showed preatherosclerotic lesions (HF RCA pre-ATH) classifiable as Stary type
I lesion (d), type II fatty streak (e), and type III lesion (f), or atheromas (black arrows, HF RCA ATH segments) classifiable as type IV ((g)
and (h)) and as type V fibroatheroma ((i), fibrous cap: asterisk). Low power micrographs, bar = 500 𝜇m, high power insets, bar = 50 𝜇m. I =
intima, M = media, A = adventitia.
Table 1: Histomorphometric results of RCA and FA segments in 6 CTRL and 6 HF cases.
CTRL RCA (6) HF FA (6) HF RCA (6) RCA pre-ATH (3) RCA ATH (3)
𝑁/𝑁tot. Stary types I–III 0/6 2/6 3/6 3/3 0/3
𝑁/𝑁tot. Stary types IV-V 0/6 0/6 3/6 0/3 3/3
IT (mm) 0.03 ± 0.02 0.06 ± 0.05 0.50 ± 0.44 0.13 ± 0.05 0.86 ± 0.36
IMT ratio (a.u.) 0.11 ± 0.04 0.15 ± 0.05 0.58 ± 0.24 0.32 ± 0.11 0.77 ± 0.07
LA (mm2) 0.04 ± 0.02 0.06 ± 0.04 2.61 ± 3.42 0.30 ± 0.27 5.00 ± 3.64
LA ratio (a.u.) 0.03 ± 0.02 0.05 ± 0.02 0.97 ± 1.13 0.14 ± 0.10 1.75 ± 1.10
Number of segments (𝑁) and average value ± SD of maximal IT (IT), maximal intima to media thickness ratio (IMT ratio), lesion area (LA), and lesion to
intact wall area ratio of FA and RCA in CTRL and HF cases are reported. RCA segments showing Stary types I–III (RCA pre-ATH) and those displaying Stary
types IV-V lesions (RCA ATH) are also grouped separately.
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Figure 2: Pie charts of the total identified proteins from CTRL and HF. (a) Identified proteins are classified, based on Gene Ontology,
according to their localization in intracellular or extracellular space. (b) Identified proteins are evaluatedwith SecretomeP software to compute
their secretion potential. They were divided into classically secreted, not classically secreted, and not predicted.
pathway related, cell membrane and associated, cytoskeleton
and associated, intracellular, and ECM associated proteins
(Figure 2(a)). The secretion potential of identified proteins
was computed by submitting them to SecretomeP tool which
uses specific databases to predict a classical secretion via
endoplasmic reticulum (presence of signal peptide) or not
classical secretion through the multivesicular bodies [23]
(Figure 2(b)).
PCA unsupervised clusters (Figure S5 in Supplementary
Material) were CTRL samples (𝑁 = 6), HF FA (𝑁 = 6), and
HF RCA (𝑁 = 6), which resulted in two subgroups (pre-
ATH and ATH,𝑁 = 3 each) histologically corresponding to
different ATS stage, as reported in Table 1.
Paired 𝑡-test evidenced 17 differentially secreted proteins
when all HF RCA samples were compared to CTRL. HF FA
samples were used only to distinguish between diet-related
and ATS-related tissue-secreted proteins. 𝑡-test between HF
FA and CTRL groups, which was used to suggest diet-related
factors, showed significant differential expression in glycer-
aldehyde 3 phosphate dehydrogenase, desmin, prelamin A/C,
glutathione peroxidase 1, and apolipoproteins A I and A IV.
Differentially expressed proteins were grouped into cel-
lular (𝑁 = 11) and extracellular matrix proteins (𝑁 = 6)
(Table 2). The putative roles of each factor in atherogenesis
and in disease-related cellular pathways, as suggested by the
literature, are reported in Table 2.
Ten out of these proteins had already been reported
in serum/plasma and listed in Human Protein Reference
database (http://www.hprd.org) and 15 resulted as predicted
to be secreted by SecretomeP software. Western blot analysis
was applied to two identified markers to validate the expres-
sion of intact proteins by an antibody-based approach and
observed by mass spectrometric analysis using expression
of digested peptides. Additionally, by comparing pre-ATH
(𝑁 = 3) and ATH (𝑁 = 3) segments (see Figure S2 in
Supplementary Material), a statistical significant difference
was observed only for CHI3L1 (𝑃 < 0.05), which resulted as
upregulated in ATH group.
The expression trends in CTRL and HF secretome sam-
ples of CHI3L1 and Cat-D were validated by Western blot,
confirming the results obtained bymass spectrometry (Figure
S1 in Supplementary Material).
3.3. Pathway Analysis and Tissue Immunohistochemistry. IPA
was used to highlight pathways and diseases which involve
secreted proteins.Themost represented pathways were those
related to cell proliferation, migration, and VSMC activation.
Among the proteins that are implicated in atherogenesis and
vascular diseases, CHI3L1 was the only one that is predicted
as linked to all pathways (Figure 3).
On the basis of these results, anti-CHI3L1 antibody was
used to quantify tissue expression of this protein and associate
it with localization of other lesional VSMC markers and
with ATS grade and morphometric indexes of lesion extent
(Figure 4).
Arterial tissue immunoreactivity to anti-CHI3L1 anti-
body was quantified as percentage of intralesional positive-
staining area in all RCA segments of CTRL and HF cases.
Anti-CHI3L1, anti-𝛼SM-actin, and anti-S100A4 antibod-
ies labelled the same region in all lesion types observed
in adjacent consecutive HF RCA sections, demonstrating a
consistent tissue codistribution. Colocalization of the three
antibodies in the same cell type was also observed in several
microscopic fields of HF RCA ATH cases (Figure 5).
ELISA for CHI3L1 detection was performed on end-
diet plasma samples of the same CTRL and HF animals
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Table 2: Differential protein expression between HF RCA and CTRL cases.
Localization Gene name Protein name Coronary HF/CTRL 𝑃 value SecretomeP Plasma Role in atherogenesis
Cellular
G3P
Glyceraldehyde-3-
phosphate
dehydrogenase
Up 0.05 √ √ Glucose metabolism
CATD Cathepsin D Up 0.009 √ √ Macrophage phagocytosis,lipid efflux [40, 41]
DESM Desmin Up 0.04 √ Focal adhesion [29]
VIME Vimentin Up 0.02 √ Focal adhesion [29]
CPNS1 Calpain Up 0.05 √ Calcium binding,proatherogenic [42]
ICAL Calpastatin Up 0.05 Not predicted Calcium binding, calpaininhibitor
MOES Moesin Up 0.005 √ Focal adhesion [43]
CH3L1 Chitinase-3-likeprotein 1 Up 0.004 √ √
Adhesion and migration
[37]
S10A6 Protein S100-A6 Up 0.05 √ √ RAGE ligand and marker ofMI [44]
LMNA Prelamin-A/C Up 0.03 Not predicted Oxidative stress, vascularaging [45]
GPX1 Glutathioneperoxidase 1 Up 0.05 √ Oxidative stress
Extracellular
matrix
PGS1 Biglycan Up 0.04 √ √ Lipoprotein retention [46]
HPLN1
Hyaluronan and
proteoglycan link
protein 1
Down 0.000033 √ √ Plaque stability,atheroprotection [47]
OSTP Osteopontin Up 0.04 √ √ Secondary carotid eventsmarker [39]
APOA1 Apolipoprotein A-I Up 0.01 √ √ HDL constituent,atheroprotection [48]
APOE Apolipoprotein E Up 0.0007 √ √ Atheroprotection [49]
APOA4 ApolipoproteinA-IV Down 0.03 √ √
Antioxidative,
atheroprotection [50]
First column: biological localization of proteins. Second column: gene name. Third column: protein names reported according to SwissProt 2013 database.
Sixth column: secretion potential as predicted according to SecretomeP software. Seventh column: presence in plasma, according to Human Protein Reference
database (http://www.hprd.org). Eighth column: roles in atherogenesis, as suggested in the literature.
and the circulatory expression of the protein resulted as
2.6 ± 0.4 ng/mL in CTRL samples (mean ± SD) and 12.4 ±
3.5 ng/mL in HF samples (mean ± SD) (𝑃 value = 0.001).
4. Discussion
Different proteomics approaches have been used to search
for biomarkers of ATS presence and severity. The majority of
these studies in humans concern carotid (from surgery) and
coronary arteries with overt disease and plaque complication
features [24].
Body fluids, particularly blood, are the samples of choice
for biomarker discovery in medicine since they can be easily
and noninvasively collected. However, plasma proteomics
profiling has turned out to be extremely challenging due
to the wide dynamic range of proteins, the corresponding
intrinsic low abundance of potential biomarkers and the
huge individual heterogeneity of the samples. For these rea-
sons, in the last years many researchers focused on the secre-
tome analysis of cells and tissues with the expectation that
identified putative biomarkers could be traced back in body
fluids with more sensitive and targeted analyses [25].
Recently, we designed and assessed a gel- and label-free
LC-MS/MS workflow that was used to produce a proteome
profile concerning human atherosclerotic carotid plaque and
secreted proteins from cultured cells [26, 27].
In the present work, the overall workflow was utilized to
study the secretome-contained proteins of coronary arterial
segments in order to characterize the early phases of plaque
formation and growth, to identify molecular markers associ-
ated with pathology grade, and to evaluate their translation
into the clinical field.
To this end, a swine model of coronary atherogenesis
was used, and atherosclerotic changes of different stage,
extent, and distribution along the three main coronaries
were observed following high fat, cholesterol-enriched diet.
Despite the overall variability of the lesion distribution in
the coronary segments that we analyzed (Table S4 in Supple-
mentary Material), a four-month high fat diet treatment was
able to induce in all cases coronary atherosclerotic changes
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Figure 3: IPA of a subset of 31 proteins identified in the secretome of
RCA specimens. Pathways were generated based on the information
stored in IPA Knowledge base. Nodes correspond to the 31 proteins
and are reported with their Gene Codes. Extracellular space,
cytoplasm, and plasma membrane proteins are shown based on IPA
classification. Relationships with disease and cellular functions are
evidenced. The relationships that are predicted to lead to activation
and to inhibition and those not predicted are reported in orange,
blue, and grey, respectively.
and at least one atheroma lesion. Conversely, no changes or
only type I preatherosclerotic initial changes were observed
in femoral arteries, a finding supported by previous studies
of porcine coronary as compared to iliac/femoral artery
atherosusceptibility during diet treatment [15, 28]. However,
we cannot exclude the idea that a comprehensive histologic
examination of all femoral segments, in addition to those
sampled for the secretome analysis, could have evidenced
more advanced atherosclerotic changes also in this artery.
LC-MS/MS analysis of the whole secretome content
allowed identifying 224 proteins, among which 17 were dif-
ferentially expressed between CTRL and HF cases.
𝑡-test between HF FA and CTRL groups, both without
significant atherosclerotic lesions, showed significant dif-
ferential expression in glyceraldehyde 3-phosphate dehy-
drogenase, desmin, prelamin, glutathione peroxidase 1, and
apolipoproteins A-I and A-IV, which was attributed to events
induced by different diets: an atherogenic diet-dependent
modulation of lipid and glucose metabolism-associated pro-
teins and diet induction of free radicals modulating fac-
tors related to oxidative stress. Comparison between RCA
segments of CTRL and HF groups showed that the most
represented differentially expressed proteins were VSMC
intracellular proteins and ECM factors related to VSMC
activation and synthesis.
Most of the VSMC proteins (moesin, vimentin, and
desmin) that resulted in upregulation in RCAHF atheroscle-
rotic samples, but not in HF FA samples, are related to
the adhesion pathway and are strongly modulated during
VSMC phenotype switch and involved in VSMC capacity to
migrate [29].Thiswas confirmed also by bioinformatics path-
way analysis (IPA software), which supported the involve-
ment of these proteins in vascular disease and in VSMC
proliferation/migration. Additionally, a relationship was
found between their expression and the lesion stage and
extent.
Furthermore, a significant modulation of ECM compo-
nents, mostly synthesized by synthetic VSMCs, such as Bigly-
can, Hyaluronan, and Osteopontin, was observed in the
secretome samples of HF RCA but not in HF FA samples.
Proteoglycans are reported to bind cytokines and growth
factors causing inflammation during ATS development [30]
and may be involved in lipid retention, thus contributing
to the early phases of lesion formation [31, 32]. Also many
apolipoproteins (apolipoproteins A-I, A-IV, and E) are mod-
ulated in our model supporting this hypothesis.
CHI3L1 was the most relevant upregulated protein iden-
tified in HF RCA samples, which was (i) differentially
expressed between CTRL, pre-ATH, and ATH samples, (ii)
strongly associated with plaque size/extent and Stary stage,
and (iii) immunohistologically related to a prevalent VSMC
plaque composition. The site-specific association with lesion
stage and size was validated for the full spectrum of diet
induced lesions in samples used for secretome analysis and
immunohistochemical characterization, enabled to establish
the tissue and cell colocalization of CHI3L1 immunoex-
pression with 𝛼SM-actin/S100A4 positive-staining areas and
migratory VSMC phenotype.
At variance with previous human studies [33, 34], we did
not observe the maximal anti-CHI3L1 immunoexpression in
macrophages and lipid laden macrophages (Figures S2 and
S3 in SupplementaryMaterial). Conversely, maximal CHI3L1
expression was found in 𝛼SM-actin/S100A4 positive cells,
supporting its prevalent synthesis in the activated VSMC
phenotype within developing atherosclerotic lesions. This
difference could be explained by the more advanced stage
and different cell composition of the complicated human
carotid plaques as compared to coronary plaques from our
experimental model of atherogenesis.
It is reported that the expression of CHI3L1 is enhanced
in aorta of patients with coronary atherosclerosis and is
significantly correlated with atherosclerotic risk factors [35],
although increased expression of CHI3L1 in human ath-
erosclerotic lesions is primarily associated with production
and activation of inflammatory factors [36]. Despite being
associatedwithVSMCpresence in atherosclerotic plaque [37]
and with VSMC activation towards a synthetic phenotype
[38], this protein has never been hitherto shown to be directly
correlated to coronaryATS grade and extent during atheroma
formation.
CHI3L1 expression was also measured by ELISA in
plasma samples of pigs fed on standard and high fat diet. The
statistically significant upregulation of its circulatory expres-
sion consolidates the association between the expression of
this marker and the presence of CAD in this experimental
model of atherogenesis and supports its amenability to be
used as marker of ATS severity in the clinical context.
Altogether, these data confirm that VSMC activation
towards a migratory/synthetic phenotype may play a pivotal
role in the early formation and progression of coronary
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Figure 4: Correlation between secreted and tissue coronary CHI3L1 expression (by LC-MS/MS analysis and immunohistochemistry, resp.)
and IMT ratio of corresponding segments at different Stary stages. Representative photomicrographs at low (bar = 200 𝜇m) and high
magnification (enlargements of intimal lesion area, insets; bar = 50 𝜇m) from CHI3L1 antibody labeled cross sections of HF RCA segments
(from (a) to (f)), according to ATS grade (Stary types I to V) demonstrate the correlation of CHI3L1 expression (dark brown staining indicates
positivity) and of ATS stage with secreted CHI3L1 values (arrows). Secreted CHI3L1 expression (blue dots) and CHI3L1 immunoreactivity,
expressed as percentage of intralesional positive cell area (red squares), hold direct and significantly linear relations (𝑅2 > 0.8) with the IMT
ratio of the same segments.
atheromas and suggest that VSMC-derived/-secreted mole-
cules can be usefully exploited as plaque stage/size related
biomarkers in CAD.
4.1. Study Limitations. Themajor drawbacks in atherogenesis
research are (i) difficulties in investigating the early phase of
the pathology in the clinical context and (ii) discrepancies
between experimental models and human characteristics of
the disease, which can limit the relevance of results. The
use of highly unbalanced diets and/or genetic manipula-
tion are the only possible choices to produce appreciable
atherosclerotic changes within few months as technically
required.The atherogenic diet adopted in our study to induce
accelerated coronary lesions in pigs could make it difficult
to extrapolate results credibly from the experimental to the
clinical context; however, the diet-independent relation to
site-specific and feature-specific characteristics of coronary
atherosclerotic plaque suggests our proteomics findings as
realistically informative in the field of marker discovery for
disease initiation and evolution.
This hypothesis is supported by the evidence that, despite
intragroup variability of lesion grade and distribution, mor-
phometric indexes of single RCA segments processed for
secretome analysis are directly and significantly related to
the average coronary values of the corresponding cases (see
Figure S4 and Table S4 in Supplementary Material), thus
extending the relevance of site-specific proteomics results to
the entire atherosclerotic coronary tree.
Despite the limited number of samples analysed, the
observation that several plaque-secreted proteins identified
in our animal model have been previously found overex-
pressed also in human atherosclerotic tissue and blood [35,
39] indirectly reinforces the translational utility of our study.
5. Conclusion
The outcomes of this study are the following:
(1) Themost relevantVSMC-secreted proteins are related
to coronary ATS stage and extent, suggesting that
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S100A4 CHI3L1𝛼SM-actin
Figure 5: Representative photomicrographs of immunostained consecutive cross sections of RCA in a typical ATH case of HF group
(immunopositive cells are dark brown). Immunostained sections demonstrate tissue codistribution (top row) and cell colocalization (middle
and bottom rows) of anti-CHI3L1 with anti-𝛼SM-actin andwith anti-S100A4 antibodies in a fibrolipid plaque. Enlargements of plaque regions
(black and red insets) are displayed in middle and bottom row, respectively. Plaque areas labelled by anti-𝛼SM-actin, anti-S100A4, and anti-
CHI3L1 antibodies are indicated (top panels, black arrows; bar = 200𝜇m) and colocalization of all three antibodies in the same cell type
evidenced (bottom panels, black arrows; bar = 10𝜇m). CHI3L1 immunopositive cells resulted also in 𝛼SM-actin or S100A4 positive or both
(middle panels, red arrows; bar = 20𝜇m).
VSMCs regulate and contribute to the initial stages
of CAD. Moreover, profiling data indicate a general
reorganization of VSMC-based pathways connected
with CAD severity, supporting the role of activated
VSMCs in the evolution of coronary lesions from fatty
streak to atheroma.
(2) CHI3L1 is the most strongly associated protein with
coronary ATS grade and extent.
(3) Immunohistochemistry suggests prevalent localiza-
tion of CHI3L1 in S100A4 positive VSMCs and sup-
ports the stage-specific distribution of this marker in
the full spectrumof coronary lesions, from initial fatty
streak to fibroatheroma.
(4) ELISA of CHI3L1 confirms a statistical significant
association between its circulatory level and the pres-
ence of CAD.
This approach can help identify circulating markers of early
plaque development and/or fast growth that could be vali-
dated in a large clinically characterized cohort of patients,
contributing to improving risk assessment of primary coro-
nary events in CAD.
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